---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091769"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:47:02.199426+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics Q2 net product sales $36.0M; narrows 2024 guidance

## Summary
- Q2 net product sales $36.0M, up from $31.8M YoY; acute care franchise $6.8M, oncology $29.2M.
- ZYNRELEF VAN PDUFA goal date set for September 23, 2024; launch expected before year-end.
- 2024 guidance narrowed: adjusted operating expenses $107-111M (prev $108-116M), adjusted EBITDA ($10) to $3M (prev ($22) to $3M).
- ZYNRELEF included in proposed 2025 NOPAIN Act as a qualifying product effective April 1, 2025.
- CrossLink partnership expanding; 561 sales representatives trained to promote ZYNRELEF to orthopedic surgeons.

## SEC filing metadata
- accession: 0000950170-24-091769
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000095017024091769/0000950170-24-091769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000095017024091769/hrtx-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091769
- JSON: https://secwatch.observer/filing/0000950170-24-091769.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091769.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.